IPI-926

05/15/2013 - "Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors."
01/01/2014 - "Additionally, IPI-926 activity was evaluated in a murine tumor xenograft model and a pharmacokinetic/pharmacodynamic relationship was examined to assess for in vivo evidence of Hh pathway hyper-responsiveness. "
05/15/2012 - "In this model, saridegib treatment induced tumor reduction and significantly prolonged survival. "
01/01/2011 - "A single dose of IPI-926 inhibited mouse stromal Gli1 transcript levels at 24 hours with unchanged human intra-tumor Gli1 levels. "
05/15/2013 - "Patients with solid tumors refractory to standard therapy were given IPI-926 once daily (QD) by mouth in 28-day cycles. "

03/01/2016 - "Although robust antitumor activity and acceptable safety were observed with the addition of IPI-926 to this regimen, future development of Hedgehog inhibitors in pancreatic cancer seems unlikely."
07/08/2011 - "It appears that hedgehog inhibition with IPI-926 was well-tolerated and might be effective in treating pancreatic cancer when combined with gemcitabine. "
01/01/2010 - "Several Shh inhibitors have not succeeded in the clinic for unknown reasons, but clinical trials in BCC and pancreatic cancer with the promising Smo antagonists GDC-0449 and IPI-926 are currently underway."
03/01/2016 - "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma. "
03/01/2016 - "This multicenter phase Ib study evaluated IPI-926 in combination with FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) in patients with advanced pancreatic cancer. "

05/15/2012 - "Here we assess the response and resistance mechanisms to the natural product derivative saridegib in an aggressive Shh-driven mouse medulloblastoma model. "
05/15/2012 - "Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model."
05/15/2012 - "Furthermore, the effect of saridegib on tumor-initiating capacity was demonstrated by reduced tumor incidence, slower growth, and spontaneous tumor regression that occurred in allografts generated from previously treated autochthonous medulloblastomas compared with those from untreated donors. "
07/23/2009 - "These studies led to the discovery of IPI-926 (compound 28), a novel semisynthetic cyclopamine analogue with substantially improved pharmaceutical properties and potency and a favorable pharmacokinetic profile relative to cyclopamine and compound 2. As a result, complete tumor regression was observed in a Hh-dependent medulloblastoma allograft model after daily oral administration of 40 mg/kg of compound 28."
02/01/2015 - "However, to date, Hh inhibitors, specifically those targeting Smoothened [such as vismodegib, BMS-833923, saridegib (IPI-926), sonidegib/erismodegib (LDE225), PF-04449913, LY2940680, LEQ 506, and TAK-441], have demonstrated good efficacy as monotherapy in patients with basal cell carcinoma and medulloblastoma, but have shown limited activity in other tumor types. "

07/01/2015 - "The clinical safety and efficacy of IPI-926 was evaluated in 14 patients with myelofibrosis in a phase II study. "
07/01/2015 - "The results did not support continued evaluation of IPI-926 as a monotherapy in myelofibrosis. "
07/01/2015 - "Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis."

11/02/2022 - "Promising results are obtained with anti-PlGF therapy, nintedanib (BIBF1120), navitoclax, IPI-926, resveratrol, and controlled hyperthermia."